Golodirsen

(Vyondys 53®)

Golodirsen

Drug updated on 11/14/2023

Dosage FormInjection (intravenous: 50 mg/mL)
Drug ClassAntisense oligonucleotides
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.

Product Monograph / Prescribing Information

Document TitleYearSource
Vyondys 53 (golodirsen) Prescribing Information.2021Sarepta Therapeutics, Inc. Cambridge, MA

Systematic Reviews / Meta-Analyses